Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery.
Publication
, Journal Article
Douglas, SR; Thomas, SM; Chiba, A; DiNome, ML; DiLalla, GA; Hwang, ES; Parrish, KM; Rosenberger, LH; Plichta, JK; Wang, T; Botty van den Bruele, AM
Published in: Ann Surg Oncol
January 2026
BACKGROUND: De-escalation of axillary surgery for hormone receptor-positive breast cancer has gained traction, but guidelines for axillary management after neoadjuvant endocrine therapy (NET) remain ill-defined. METHODS: Female patients age ≥50 years with clinical T1-4c, N0-1, ER+/HER2-
Duke Scholars
Published In
Ann Surg Oncol
DOI
EISSN
1534-4681
Publication Date
January 2026
Volume
33
Issue
1
Start / End Page
95 / 107
Location
United States
Related Subject Headings
- Survival Rate
- Sentinel Lymph Node Biopsy
- Receptors, Progesterone
- Receptors, Estrogen
- Receptor, erbB-2
- Receptor, ErbB-2
- Prognosis
- Oncology & Carcinogenesis
- Neoadjuvant Therapy
- Middle Aged
Citation
APA
Chicago
ICMJE
MLA
NLM
Douglas, S. R., Thomas, S. M., Chiba, A., DiNome, M. L., DiLalla, G. A., Hwang, E. S., … Botty van den Bruele, A. M. (2026). Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery. Ann Surg Oncol, 33(1), 95–107. https://doi.org/10.1245/s10434-025-18225-5
Douglas, Sasha R., Samantha M. Thomas, Akiko Chiba, Maggie L. DiNome, Gayle A. DiLalla, E Shelley Hwang, Kendra Modell Parrish, et al. “Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery.” Ann Surg Oncol 33, no. 1 (January 2026): 95–107. https://doi.org/10.1245/s10434-025-18225-5.
Douglas SR, Thomas SM, Chiba A, DiNome ML, DiLalla GA, Hwang ES, et al. Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery. Ann Surg Oncol. 2026 Jan;33(1):95–107.
Douglas, Sasha R., et al. “Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery.” Ann Surg Oncol, vol. 33, no. 1, Jan. 2026, pp. 95–107. Pubmed, doi:10.1245/s10434-025-18225-5.
Douglas SR, Thomas SM, Chiba A, DiNome ML, DiLalla GA, Hwang ES, Parrish KM, Rosenberger LH, Plichta JK, Wang T, Botty van den Bruele AM. Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery. Ann Surg Oncol. 2026 Jan;33(1):95–107.
Published In
Ann Surg Oncol
DOI
EISSN
1534-4681
Publication Date
January 2026
Volume
33
Issue
1
Start / End Page
95 / 107
Location
United States
Related Subject Headings
- Survival Rate
- Sentinel Lymph Node Biopsy
- Receptors, Progesterone
- Receptors, Estrogen
- Receptor, erbB-2
- Receptor, ErbB-2
- Prognosis
- Oncology & Carcinogenesis
- Neoadjuvant Therapy
- Middle Aged